Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension

INTRODUCTION: A major determining factor on outcomes in patients with pulmonary arterial hypertension (PAH) is right ventricular (RV) function. Ranolazine, which is currently approved for chronic stable angina, has been shown to improve RV function in an animal model and has been shown to be safe in...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Open Heart
Glavni autori: Han, Yuchi, Forfia, Paul R, Vaidya, Anjali, Mazurek, Jeremy A, Park, Myung H, Ramani, Gautam, Chan, Stephen Y, Waxman, Aaron B
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2018
Teme:
Pulmonary Vascular Disease
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5845423/
https://ncbi.nlm.nih.gov/pubmed/29531764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/openhrt-2017-000736
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items